Inverse Agonism Explained

## Introduction

Inverse agonists suppress the basal (constitutive) activity of receptors that are spontaneously active in the absence of any ligand. This concept fundamentally challenged the classical pharmacological view that receptors are silent without an agonist and that antagonists merely block agonist access without affecting baseline signaling.

## Constitutive Receptor Activity

Many GPCRs exist in a thermodynamic equilibrium between inactive (R) and active (R*) conformations. Even without an agonist bound, a fraction of receptors spontaneously adopt the R* state, producing measurable basal signaling. The level of constitutive activity varies by receptor type and expression level. Wild-type histamine H3 receptors, cannabinoid CB1 receptors, and many mutant oncogenic receptors exhibit significant constitutive activity.

Constitutive activity increases with receptor overexpression—more total receptors means more spontaneously active R* conformations, which is relevant in cancers with receptor gene amplification.

## How Inverse Agonists Work

Inverse agonists preferentially bind and stabilize the inactive R conformation, shifting the R↔R* equilibrium away from the active state. This reduces signaling below the basal level—the opposite of what an agonist achieves.

The efficacy spectrum runs continuously from full agonist (+1) through partial agonist, neutral antagonist (0), partial inverse agonist, to full inverse agonist (-1). A neutral antagonist binds R and R* with equal affinity and blocks both agonist and inverse agonist access without altering constitutive activity.

## Clinical Relevance

Many drugs historically classified as antagonists are pharmacologically inverse agonists. This distinction becomes clinically important when constitutive activity contributes to disease pathology:

- **Antihistamines** (cetirizine, loratadine): Inverse agonists at H1 receptors that suppress tonic H1 signaling driving allergic inflammation
- **Beta-blockers** (carvedilol, metoprolol): Most are inverse agonists at beta receptors, reducing constitutive cardiac contractility in heart failure
- **Rimonabant**: CB1 inverse agonist for obesity (withdrawn due to psychiatric adverse effects)
- **Pimavanserin**: 5-HT2A inverse agonist approved for Parkinson's disease psychosis

## When Inverse Agonism Matters

The distinction is significant in gain-of-function receptor mutations (constitutively active oncogenes), elevated basal GPCR signaling (heart failure), and high tonic endocannabinoid signaling. In these contexts, a neutral antagonist would be insufficient—only an inverse agonist suppresses the pathological basal activity.

## Key Takeaways

- Many receptors are constitutively active, signaling without agonist binding
- Inverse agonists stabilize the inactive R state, reducing activity below baseline
- Most classical “antagonists” are technically inverse agonists at GPCRs
- Clinical impact depends on the degree of constitutive receptor activity in disease